ANGELA QUACH: Open Payments
NPI 1770053860 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,866 in 36 payments from 15 companies in 2025. Trend: 2023 $1,913 · 2024 $2,098 · 2025 $1,866
Food & beverage: $1,573Education: $293
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 3 | $332 |
| Lilly USA, LLC | 4 | $253 |
| SOBI, INC | 4 | $206 |
| Incyte Corporation | 3 | $183 |
| Syndax Pharmaceuticals, Inc. | 5 | $166 |
| GlaxoSmithKline, LLC. | 1 | $123 |
| Adaptive Biotechnologies Corporation | 1 | $118 |
| AstraZeneca Pharmaceuticals LP | 3 | $98 |
| Astellas Pharma US Inc | 3 | $97 |
| Novartis Pharmaceuticals Corporation | 3 | $89 |
Products named: Vemlidy, JAKAFI, AREXVY, clonoSEQ, Vonjo, CALQUENCE, SCEMBLIX, Cresemba.
Industry payments across TX — which companies pay providers there.
